A double-blind, randomized, controlled trial of rifaximin compared to vancomycin for the treatment of Clostridium difficile-associated diarrhea (CDAD).

Trial Profile

A double-blind, randomized, controlled trial of rifaximin compared to vancomycin for the treatment of Clostridium difficile-associated diarrhea (CDAD).

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Rifaximin; Vancomycin
  • Indications Clostridium infections; Diarrhoea
  • Focus Registrational; Therapeutic Use
  • Sponsors Salix Pharmaceuticals; Valeant Pharmaceuticals International
  • Most Recent Events

    • 19 May 2012 Primary endpoint 'Clinical-response' has not been met.
    • 14 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top